[1] Xu X, Hu H, Lin Y, et al. Differences in Leukocyte Telomere Length between Coronary Heart Disease and Normal Population: A Multipopulation Meta-Analysis[J]. Biomed Res Int, 2019,2019:5046867.
[2] Brautbar A, Ballantyne C M. Pharmacological strategies for lowering LDL cholesterol: statins and beyond[J]. Nat Rev Cardiol, 2011,8(5):253-265.
[3] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023)[J]. 中国循环杂志, 2023,38(3):237-271.
[4] Guo Y, Yan B, Tai S, et al. PCSK9: Associated with cardiac diseases and their risk factors[J]. Arch Biochem Biophys, 2021,704:108717.
[5] Ding Z, Wang X, Liu S, et al. PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy[J]. Cardiovasc Res, 2018,114(13):1738-1751.
[6] Silverman M G, Ference B A, Im K, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis[J]. JAMA, 2016,316(12):1289-1297.
[7] Davidson M H. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction[J]. J Clin Lipidol, 2013,7(3 Suppl):S11-S15.
[8] Cunningham D, Danley D E, Geoghegan K F, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia[J]. Nat Struct Mol Biol, 2007,14(5):413-419.
[9] Deedwania P, Murphy S A, Scheen A, et al. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial[J]. JAMA Cardiol, 2021,6(2):139-147.
[10] Ota H, Omori H, Kawasaki M, et al. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study[J]. Eur Heart J Cardiovasc Imaging, 2021.
[11] 超高危动脉粥样硬化性心血管疾病患者血脂管理中国专家共识[J]. 中华心血管病杂志, 2020(4):280-281.
[12] Rosenson R S, Hegele R A, Fazio S, et al. The Evolving Future of PCSK9 Inhibitors[J]. J Am Coll Cardiol, 2018,72(3):314-329.
[13] Wong N D, Shapiro M D. Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials[J]. Front Cardiovasc Med, 2019,6:14.
[14] Nicholls S J, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial[J]. JAMA, 2016,316(22):2373-2384.
[15] Koskinas K C, Windecker S, Pedrazzini G, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)[J]. J Am Coll Cardiol, 2019,74(20):2452-2462. |
